

**Anti-Oxyntomodulin (human)  
Mouse monoclonal antibody**

Subclass:

Clone: 20

CAT. NO.

**ABS 059-20**

---

SPECIFICITY	ABS 059-20 is specific for human oxyntomodulin. Cross-reacts fully with glucagon.
IMMUNOGEN	Synthetic full length oxyntomodulin coupled to carrier.
TESTED APPLICATIONS	ELISA
SPECIES REACTIVITY (POSITIVE)	Human, mouse and rat.
SPECIES REACTIVITY (NEGATIVE)	Not determined.
EPITOPE SPECIFICITY	ABS 059-20 has a different epitope specificity than ABS 064-46 and ABS 064-23.

---

PRESENTATION

Content:	Available in 400 µL and 1 ml size. 1 mg/ml +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	2-8°C

---

**APPLICATION** **ELISA:** ABS 064-46 (as capture antibody) forms a sandwich ELISA pair with ABS 059-20B (as biotinylated detection antibody) for measuring Oxyntomodulin. ABS 064-46 is specific for oxyntomodulin and does not cross-react with glucagon.

**TARGET** Oxyntomodulin is a peptide hormone of 37 amino-acid residues (29-amino acid sequence of glucagon, with an 8-amino acid carboxy-terminal extension) produced by the L cells of the gut. It modulates gastric acid secretion from the oxyntic cells of the stomach, inhibits appetite and has glucose lowering effects. Oxyntomodulin is produced by cell-type-specific processing of proglucagon that forms glicentin, GLP-1 and GLP-2 as well in the L cells of the intestinal mucosa.

REFERENCES

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.